Introduction
============

Although salivary gland adenoid cystic carcinoma (ACC) is a rare disease with roughly 500 cases annually in the USA ([@b1-ijo-49-01-0225]), the prognosis is grave due to the clinical behavior of ACC, such as indolent growth, but frequent perineural invasion and distant metastasis ([@b2-ijo-49-01-0225],[@b3-ijo-49-01-0225]). ACCs are currently managed by surgery, with postoperative radiotherapy utilized for the more aggressive cases. The effectiveness of adjuvant chemotherapy or targeted therapy to date has been limited. No molecular biomarkers are yet available that can either be used to predict the chemotherapeutic response or prognosis of ACC, or serve as chemotherapeutic targets, and is due to the fact that the molecular pathogenesis remains poorly understood ([@b2-ijo-49-01-0225],[@b4-ijo-49-01-0225]).

Recent whole-genome and exome sequencing studies ([@b5-ijo-49-01-0225],[@b6-ijo-49-01-0225]) have confirmed some known mutations and uncovered a handful of new genomic alterations in the ACC mutational landscape, such as somatic driver mutations in PIK3CA, FGFR2, NOTCH1/2 and the negative NOTCH signaling regulator, SPEN ([@b6-ijo-49-01-0225]). Ho *et al* ([@b5-ijo-49-01-0225]) found somatic mutations in genes belonging to the DNA damage response and protein kinase A signaling pathways. Both Ho *et al* ([@b5-ijo-49-01-0225]) and Stephens *et al* ([@b6-ijo-49-01-0225]) identified a high percentage of mutations in chromatin regulating genes that are epigenetic modifiers of gene activity ([@b5-ijo-49-01-0225],[@b6-ijo-49-01-0225]). Some of the genetic alterations uncovered by sequencing studies corroborated the previous findings from molecular studies of ACC, such as KIT overexpression ([@b7-ijo-49-01-0225]--[@b10-ijo-49-01-0225]). Notably, several oncogenes and tumor suppressor genes that are altered at high frequency in other types of solid tumors, such as CDKN2A, TP53, EGFR, ERBB2 and PTEN ([@b11-ijo-49-01-0225]), appear unaffected or rarely altered in ACC ([@b5-ijo-49-01-0225],[@b6-ijo-49-01-0225],[@b11-ijo-49-01-0225]). The FGF-IGF-PI3K pathway is among these; the Stephen *et al* found no genetic mutations in this pathway ([@b6-ijo-49-01-0225]), while Ho *et al* ([@b5-ijo-49-01-0225]) found recurrent mutations in the FGF-IGF-PI3K pathway in only 30% of ACCs. Furthermore, similarly to that found previously by next-generation sequencing in 24 ACCs ([@b6-ijo-49-01-0225]), Stephens *et al* recently found similar, low frequency of genomic alterations in 28 cases of the relapsed and metastatic ACCs by the same sequencing technique ([@b12-ijo-49-01-0225]). Again, like in the 24 primary ACCs ([@b6-ijo-49-01-0225]), these genetic alterations found in the relapsed and metastatic ACCs were also low frequency events, compared with these same genetic alterations seen in the more common solid tumors ([@b12-ijo-49-01-0225]). This suggests that the low frequency of genomic alterations may not account for the relapse and metastasis of ACCs. Taken together, although some novel and known genetic alterations have been identified in ACCs and these genomic alterations may contribute to the molecular pathogenesis of ACC, the relatively low frequency of any genetic mutation uncovered in primary, relapsed, and metastatic ACCs suggests that epigenetic alterations may also contribute in an important way to the pathogenesis of ACC ([@b11-ijo-49-01-0225]).

The molecular pathogenesis of ACC still remains unclear. The most common molecular alterations found in ACC are the t(6;9)(q22-23;p23-24) translocation resulting in the MYB-NFIB fusion gene, which occurs in 29 to 86% of ACCs ([@b3-ijo-49-01-0225],[@b5-ijo-49-01-0225],[@b6-ijo-49-01-0225],[@b13-ijo-49-01-0225]--[@b16-ijo-49-01-0225]), and overexpression of the MYB protein, observed in 89--97% of ACCs ([@b15-ijo-49-01-0225],[@b16-ijo-49-01-0225]). The role of these two molecular alterations in ACC pathogenesis is not well understood. MYB overexpression is often ([@b15-ijo-49-01-0225],[@b17-ijo-49-01-0225]), but not always ([@b13-ijo-49-01-0225]--[@b16-ijo-49-01-0225],[@b18-ijo-49-01-0225]), associated with the MYB-NFIB fusion, multiple MYB-NFIB fusion variants due to the differential breakpoints have also been reported ([@b13-ijo-49-01-0225]), and NFIB has been found to fuse with non-MYB partners in ACC ([@b19-ijo-49-01-0225]), so that the relationship between these two molecular events is also unclear. Neither MYB-NFIB fusion nor MYB overexpression has consistently been found to be associated with prognostic features. Therefore, while improved understanding of these alterations is imperative for elucidating the pathogenesis of ACC, it is also necessary to explore additional aspects of the unique pathology of ACC.

In the present study, we utilized a global demethylating agent, 5-aza-2′-deoxycytidine (5-AZA), to unmask silencing of putative TSGs in ACC xenograft models and a DNA methylation array to identify oncogene and TSG candidates under the control of promoter methylation in ACC. Our approach was to circumvent the lack of viable ACC cell lines ([@b20-ijo-49-01-0225]) by using primary xenograft tumor models, in an attempt to identify relevant genes exhibiting differential promoter methylation.

Materials and methods
=====================

Genomic DNA extraction from mouse xenografts of ACC tumors
----------------------------------------------------------

Freshly resected ACC tumors from three different patients were transplanted in nude mice to establish ACC xenografts. The establishment of mouse xenografts with ACC tumor has been reported ([@b21-ijo-49-01-0225]). When the xenografts reached 125--250 mm^3^, mice were randomly assigned into two groups, control and treatment. The control group had 2 mice; the treatment group had 3 mice. The control group of 2 mice received no injection. In contrast, the mice in the treatment group received a daily subcutaneous injection of 5-aza-2′-deoxycytidine (5-Aza) at a dose of 1 mg/kg of body weight for 28 days by the South Texas Accelerated Research Therapeutics Co. (San Antonio, TX, USA). 5-Aza is a nucleoside analog that has been shown to cause hypomethylation of genes at a low dose ([@b22-ijo-49-01-0225]--[@b24-ijo-49-01-0225]) by depleting DNA methyltransferase 1 ([@b25-ijo-49-01-0225],[@b26-ijo-49-01-0225]) and this demethylation at CpG islands in the gene promoter can often re-activate gene expression of the once methylation-silenced gene ([@b27-ijo-49-01-0225]).

After the termination of the treatment, these xenografts of ACC tumors were harvested, snap-frozen in liquid nitrogen, and stored at −80°C before genomic DNA extraction. Two samples were harvested from each xenograft from each mouse.

The DNA was extracted from the same xenograft using AllPrep DNA/RNA Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer\'s instructions.

Methylation array and expression array of mouse xenografts of ACC tumors
------------------------------------------------------------------------

The extracted DNAs from mouse xenografts of ACC tumors were submitted to the Johns Hopkins University core facility for genome-wide DNA methylation screening using the Illumina Infinium HumanMethylation27 BeadChip array (Illumina, Inc., San Diego, CA, USA), according to the manufacturer\'s instructions. The quality of all DNA samples was subjected to quality control by Agilent\'s Bioanalyzer before methylation array.

Human tissue samples
--------------------

Formalin-fixed, paraffin-embedded (FFPE) samples were obtained from 32 patients treated surgically by the Department of Otolaryngology-Head and Neck Surgery of the Johns Hopkins Medical Institutions between the years 1999 and 2009. Tissue blocks with high tumor yield were selected after all blocks had been reviewed by an experienced head and neck pathologist (J.A.B.) to confirm the diagnosis of ACC. Four sections of 20 μm thickness were cut from each block and manually micro-dissected to yield \~80% tumor purity. In addition, 20 FFPE parotid or submandibular glands that were resected either for benign disease or as part of other surgical procedures from 20 patients treated surgically by the Department of Otolaryngology-Head and Neck Surgery of the Johns Hopkins Medical Institutions between the years 1999 and 2004 were included in the present study after histologic confirmation that the tissues to be used were distant from any benign or inflammatory lesion. All tissues were obtained with the approval of the Johns Hopkins Institutional Review Board.

DNA extraction from frozen and FFPE tissues
-------------------------------------------

Genomic DNA was extracted from the frozen samples of 6 normal control salivary gland tissues and 6 ACC primary tumor tissues and from microdissected FFPE tissue sections on glass slides (normal and ACC tumor) using the SDS-PK method as described previously ([@b28-ijo-49-01-0225],[@b29-ijo-49-01-0225]). Briefly, a small piece of each frozen tissue (normal and ACC tumor) was cut-off using a disposable single-edge razor blade, and then collected in a 1.5-ml Eppendorf tube.

Each FFPE tissue section on a glass slide was scraped off by a disposable single-edge razor blade and then collected in a 1.5-ml Eppendorf tube to undergo deparaffinization in xylenes on a heat block in the fume hood. Xylenes were removed when deparaffinization was complete. Residual amount of xylene in each sample was washed 3 times by 100% ethanol.

Each frozen or FFPE sample was then digested in 0.02% (50 μg/ml) proteinase K (Roche, Indianapolis, IN, USA) reconstituted in 1% sodium dodecyl sulfate (SDS) at 48°C for up to 72 h until no visible tissue was seen. DNA was then purified by phenol-chloroform extraction and ethanol precipitation. DNA was subsequently resuspended in LoTE buffer (10 mM Tris-HCl and 2.5 mM EDTA), and the DNA concentration was quantified using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). DNA was stored at −20°C until further use.

Bisulfite treatment and bisulfite genomic sequencing (BS-seq) of ACC and control genomic DNAs
---------------------------------------------------------------------------------------------

The EpiTect Bisulfite kit (Qiagen) was used to convert unmethylated cytosines in genomic DNA extracted from frozen samples and FFPE samples (normal and ACC tumor) to uracils, according to the manufacturer\'s instructions ([@b29-ijo-49-01-0225]). Bisulfite converted xenograft genomic DNA samples were stored at −80°C until use.

The criteria used to select genes and a region in a given gene for validation by BS-seq from the list of methylated genes detected by methylation array (data not shown) were that: i) the region selected for validation by BS-seq had to be in the promoter region (5 kb) or 5′-UTR exons. We did not necessarily validate the region corresponding to the probe set ID in methylation array. ii) There was at least one CpG island in the promoter region (5 kb) and the 5′-UTR exons were detected by MethPrimer ([@b30-ijo-49-01-0225]) in a given gene. iii) Twenty genes selected for validation were among top 100 candidates in the gene list; the rest (12 genes) were not among top candidates, but also included due to general interest.

Validation of the 32 selected candidate genes from the methylation array was performed by BS-seq in a separate cohort of 6 ACC primary tumors and 6 normal control parotid salivary gland tissues. In brief, bisulfite-treated DNA was amplified with their primers designed using MethPrimer ([@b30-ijo-49-01-0225]) to span areas of CpG island(s) in their promoters or with β-actin primers.

Specifically for HCN2, there are several CpG islands in its proximal promoter and 5′-UTR exon (53 bp), but bisulfite sequencing primer sets that span areas of the CpG island(s) were not available due to the high density of CpGs. The amplified area evaluated by BS-seq for the HCN2 promoter is illustrated in [Figs. 1](#f1-ijo-49-01-0225){ref-type="fig"} and [2](#f2-ijo-49-01-0225){ref-type="fig"}. HCN2 and β-actin primer sequences were specifically designed to contain no CG dinucleotides. The HCN2 primer sequences were: forward, 5′-GGA GGT ATT GGG GGT ATA GTT GTA T-3′, which is located at -901 bases to -877 bases upstream of ATG (the start codon) and reverse, 5′-CCA ACC AAA CAA AAA AAA CTA AAA A-3′, which is located at -656 bases to -632 bases upstream of ATG. β-actin primers were: forward, 5′-TGG TGA TGG AGG AGG TTT AGT AAG T-3′ and reverse, 5′-AAC CAA TAA AAC CTA CTC CTC CCT TAA-3′. Touch-down PCR was performed for all converted DNA samples. All PCR products were purified using the QIAquick Gel Extract PCR Purification kit (Qiagen), according to the manufacturer\'s instructions ([@b29-ijo-49-01-0225]). Purified PCR products were then submitted to GeneWiz Inc. (Frederick, MD, USA) for sequencing with one of the touch-down PCR primers. The criteria to determine methylation in the electropherograms of the purified PCR products were used as previously reported ([@b31-ijo-49-01-0225]).

Quantitative methylation-specific PCR (qMSP) by TaqMan assay
------------------------------------------------------------

qMSP conditions and data interpretation were previously described ([@b28-ijo-49-01-0225],[@b32-ijo-49-01-0225]). Leukocyte DNA from a healthy individual was first methylated *in vitro* with excess *Sss*I methyltransferase (New England Biolabs, Ipswich, MA, USA) to generate universally methylated genomic DNA according to the manufacturer\'s instruction, and then this universally methylated genomic DNA was treated with the EpiTect Bisulfite kit (Qiagen) to convert unmethylated cytosines in leukocyte DNA to uracil, according to the manufacturer\'s instructions ([@b29-ijo-49-01-0225]). These universally methylated, bisulfite converted leukocyte DNA was made in a serial of 10-fold dilutions (90--0.009 ng) to construct two calibration curves (HCN2 and β-actin) for each 384-well microtiter plate on each run. All samples were within the range of sensitivity and reproducibility of the TaqMan assay based on the amplification of the internal reference standard, β-actin (threshold cycle value for β-actin of ≤40), as previously reported ([@b31-ijo-49-01-0225]). The relative level of methylated DNA in each sample was determined as a ratio of qMSP-amplified HCN2 gene to β-actin (reference gene) and then multiplied by 100 for easier tabulation (average value of triplicates of the gene of interest divided by the average value of triplicates of β-actin x 100). The *HCN2* qMSP primer sequences were designed by MethPrimer and their sequences were: forward, 5′-GTA TAG TTG TAT TCG GAG TTC G-3′, which is located at -889 bases to -868 bases upstream of ATG and reverse, 5′-AAC AAT ACC CTA AAA AAC CGT ACG-3′, which is located at -742 bases to -719 bases upstream of ATG. The *HCN2* probe (sense) was manually designed and its sequence was 5′-/56-FAM/TCG GGG AAA GGA GGT AAT TTC GGG/36-TAMSp/-3′, which is located at -862 bases to -839 bases upstream of ATG ([Figs. 1](#f1-ijo-49-01-0225){ref-type="fig"} and [2](#f2-ijo-49-01-0225){ref-type="fig"}).

qMSP was carried out using the following conditions: 95°C for 5 min, followed by 45 cycles at 95°C for 15 sec and 60°C for 1 min.

ACC tissue microarray (TMA), detection of MYB-NFIB fusion by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) staining
----------------------------------------------------------------------------------------------------------------------------------------------

An ACC TMA was constructed in house. This TMA comprises of the cores of 93 ACC tumors and 10 normal salivary gland tissues. As previously reported ([@b3-ijo-49-01-0225]), FISH was performed on formalin-fixed paraffin-embedded sections in this ACC TMA to detect MYB-NFIB fusion. For IHC, a mouse monoclonal HCN2 antibody (S71-37) was obtained from Novus Biologicals LLC (Littleton, CO, USA). HCN2 antibody was validated in house using positive control tissue sections (heart and brain) before it was used for IHC staining on ACC TMA sections. IHC staining was evaluated by a pathologist with expertise in the area of head and neck (J.A.B.) As previously reported ([@b33-ijo-49-01-0225]), each sample was assigned an H-score, which is the product of percentage of cells in each sample with positive staining (range, 0--100%) multiplied by the intensity of staining (range, 0--3).

Statisticalanalysis, methods, and bioinformatics
------------------------------------------------

Retrospective medical record abstraction was carried out to ascertain clinical and pathologic variables of interest.

Methylation level for HCN2 and IHC H-scores were considered as continuous variables and reported as median and interquartile range (IQR), or as binary variables categorized as \<median or ≥median. Median methylation level and H-score were compared in ACC cases vs. controls, and then across clinicopathological variables of interest among cases, using the non-parametric Wilcoxon rank-sum test for binary variables and the non-parametric Kruskall Wallis test for categorical variables. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. Disease-free survival (DFS) was calculated from the date of diagnosis to the date of any (local, regional or distant) recurrence. Patients with distant metastases at the time of diagnosis, or who died of incident disease without recurrence, were excluded from DFS analysis. OS and DFS by binary methylation status of HCN2 gene (categorized as \< median or ≥ median) were reported as median and standard error (SE) and estimated using the Kaplan-Meier method and compared using the log-rank test for equality of survival functions. Pairwise correlation analysis was used to determine correlation between methylation level and H-score.

Data analysis was performed using STATA 11.2 (StataCorp LP, College Station, TX, USA). P-values \<0.05 were considered statistically significant.

Results
=======

Differentially methylated genes identified by methylation array
---------------------------------------------------------------

The genome-wide methylation array identified 3,481 genes (data not shown) that were significantly differentially methylated in ACC tumors that were treated with 5-Aza, compared with control ACC tumors that received no treatment. Among these genes, 32 candidate genes ([Table I](#tI-ijo-49-01-0225){ref-type="table"}) were selected for validation by BS-seq in a small set composed of 6 ACC and 6 normal frozen tissues.

Among these 32 genes, FRMD6 and RGPD3, were methylated in both normal and ACC tumor samples by BS-seq ([Table I](#tI-ijo-49-01-0225){ref-type="table"}). Using BS-seq, 10 CpG dinucleotides were reliably sequenced in HCN2 (NM_001194), as illustrated in [Figs. 1](#f1-ijo-49-01-0225){ref-type="fig"} and [2](#f2-ijo-49-01-0225){ref-type="fig"}. The differential methylation status was confirmed between normal and ACC ([Table II](#tII-ijo-49-01-0225){ref-type="table"}). Among these 10 CpGs, 5 CpG sites were methylated in all normal samples, whereas other 5 CpG sites were methylated in most of the normal samples. No methylation, except 1 CpG (CpG \#4) in 2 samples, was found in all 6 ACC tumor tissues ([Table II](#tII-ijo-49-01-0225){ref-type="table"}). The differential methylation status detected by the methylation array for the rest of the top 32 genes was found to be without differential methylation between normal and ACC tumor samples on BS-seq analysis ([Table I](#tI-ijo-49-01-0225){ref-type="table"}). These data indicate that these specific CpGs on the promoter region of HCN2 could be demethylated during the carcinogenesis of ACC.

Validation of the differential methylation of HCN2 by quantitative methylation-specific PCR (qMSP)
--------------------------------------------------------------------------------------------------

A separate cohort of normal (n=20) and ACC tumor (n=32) FFPE samples were used to further validate by qMSP the differential methylation status of HCN2 in the same proximal promoter region detected by BS-seq. Further qMSP validation of HCN2 promoter methylation levels confirmed the hypomethylation of the same region in this cohort of ACC tumor FFPE samples ([Table III](#tIII-ijo-49-01-0225){ref-type="table"} and [Fig. 3](#f3-ijo-49-01-0225){ref-type="fig"}; P=0.04). These data indicate that promoter demethylation of HCN2 could be a frequent event in the carcinogenesis of ACC.

Comparison of HCN2 promoter methylation with clinico-pathological parameters
----------------------------------------------------------------------------

After confirming that the promoter region of HCN2 is significantly hypomethylated in ACC compared to normal tissue, we investigated whether the quantitative methylation status of the HCN2 promoter in ACC specimens was associated with clinicopathological characteristics ([Table III](#tIII-ijo-49-01-0225){ref-type="table"}). Patients who developed disease recurrence had significantly lower HCN2 promoter methylation levels than those who did not (0 vs. 5.4, P=0.02; [Table III](#tIII-ijo-49-01-0225){ref-type="table"} and [Fig. 4](#f4-ijo-49-01-0225){ref-type="fig"}). The same was true when considering only local recurrence (0 vs. 3.0, P=0.03) and only new distant metastases (0 vs. 4.0, P=0.05). Thus, hypomethylation of the HCN2 promoter region may increase the risk of local and distant tumor recurrence. In addition, as previously reported ([@b3-ijo-49-01-0225]), the local (9 out of 31 cases) and distant (11 out of 31 cases) recurrences were the predominant recurrences and the regional (1 out of 31 cases) recurrence was rare in this cohort of ACCs.

Since the MYB-NFIB fusion gene and MYB over-expression are found in most ACC patients ([@b13-ijo-49-01-0225],[@b19-ijo-49-01-0225],[@b34-ijo-49-01-0225]), the presence of the MYB-NFIB fusion gene was examined. There were 11 MYB-NFIB translocation-negative patients and 14 MYB-NFIB translocation-positive patients ([Table III](#tIII-ijo-49-01-0225){ref-type="table"}). No correlation was found between MYB overexpression and HCN2 promoter hypomethylation ([Table III](#tIII-ijo-49-01-0225){ref-type="table"}, P=0.22), indicating that HCN2 promoter demethylation occurred independently of MYB-NFIB translocation in this cohort.

The differential methylation status in the proximal region of HCN2 promoter was not correlated with DFS (P=0.78, log-rank test; [Table IV](#tIV-ijo-49-01-0225){ref-type="table"} and [Fig. 5](#f5-ijo-49-01-0225){ref-type="fig"}) or OS (P=0.56, log-rank test; [Table IV](#tIV-ijo-49-01-0225){ref-type="table"} and [Fig. 5](#f5-ijo-49-01-0225){ref-type="fig"}).

HCN2 IHC staining was performed on a tissue microarray (TMA) sections comprised of ACC tumors (n=93) and normal salivary gland tissue cores as controls (n=10). The HCN2 staining intensity (P\<0.001) and H-score (P=0.01), but not the percentage of the positively stained cells (P=0.10), were significantly stronger in normal control tissues than those of ACC tissues ([Table V](#tV-ijo-49-01-0225){ref-type="table"} and [Figs. 6](#f6-ijo-49-01-0225){ref-type="fig"}[](#f7-ijo-49-01-0225){ref-type="fig"}--[8](#f8-ijo-49-01-0225){ref-type="fig"}). However, IHC parameters were not significantly correlated with HCN2 promoter methylation level (P=0.67), clinicopathological characteristics (P\>0.09 for all), or survival (DFS P=0.74, OS P=0.53; log-rank test).

Discussion
==========

While there is increasing insight being gained into the genetic alterations in ACC, the epigenetic landscape remains somewhat unknown. Our objective was to use a novel method to identify differentially methylated genes in ACC in an attempt to broaden our understanding of its pathogenesis. Currently, there are no FDA-approved chemotherapeutic drugs available for the treatment of ACC, and there is a need to find targetable molecular alterations to develop effective adjuvant treatment options.

The regulation of gene expression of oncogenes and tumor suppressor genes (TSGs) through DNA promoter methylation plays an important role in the carcinogenesis of many types of human cancers ([@b27-ijo-49-01-0225]) and may also play a role in the carcinogenesis of ACC. In fact, the methylome of ACC has been profiled ([@b35-ijo-49-01-0225]) with four genes validated ([@b35-ijo-49-01-0225]).

We used a xenograft-based pharmacological demethylation and genome-wide methylation array approach, as there is a lack of viable cell lines ([@b20-ijo-49-01-0225]) in which to perform these studies. Through this non-biased screening for genes whose promoters were under the control of methylation in ACC patients, we have identified HCN2 as a putative oncogene whose promoter was hypomethylated in ACC patients. The hypomethylation of HCN2 promoter suggests that HCN2 may act as an oncogene in the pathogenesis of ACC. Furthermore, the hypomethylation in the HCN2 promoter is correlated with the any recurrence, local recurrence, and distant metastasis of ACC primary tumors.

Hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 (HCN2) belongs to a non-selective cation channel family that has 4 members, HCN1-4. The molecular identity of HCN channels remained unknown until the first member of HCN was cloned from mouse brain ([@b36-ijo-49-01-0225],[@b37-ijo-49-01-0225]) and the other members were later cloned ([@b38-ijo-49-01-0225]--[@b43-ijo-49-01-0225]). HCN isoforms were not originally named as HCNs, but the HCN nomenclature was proposed and adopted later ([@b44-ijo-49-01-0225],[@b45-ijo-49-01-0225]). HCN channels were originally named I~f~ (f for 'funny'), I~h~ (h for hyperpolarization activated), or I~q~ (q for queer in neurons), based on the unique electrophysiological properties of the current that HCN channels carry ([@b44-ijo-49-01-0225],[@b46-ijo-49-01-0225]). Furthermore, HCN1-4 share \~60% sequence identity of each other.

All four HCN channels share one unusual property-activation by a hyperpolarized cell membrane potential. HCN channels open upon hyperpolarization of the cell membrane potential and close at a positive cell membrane potential. They all also share another property, a cyclic nucleotide binding domain (CNBD) for cAMP and cGMP in their C-termini. Because they contain a CNBD, their activity can be furthermore modulated by hormones and neurotransmitters that regulate the productions of cAMP and cGMP to control heart rate and rhythm as well as neuronal pacemaking. The binding of cAMP and cGMP make HCNs active even at positive cell membrane potential ([@b44-ijo-49-01-0225],[@b46-ijo-49-01-0225]). HCNs are slow activating, inward non-selective cation channels. The current of HCNs is carried by K^+^ and Na^+^ (ratio 4:1) ([@b44-ijo-49-01-0225],[@b46-ijo-49-01-0225]). In addition, HCN channels exist as tetramers on cell membrane ([@b44-ijo-49-01-0225],[@b46-ijo-49-01-0225]).

HCN4 is predominantly expressed in the sinoatrial (SA) node of heart, while HCN2 is predominantly expressed in ventricular cardiomyocytes and also in the sinoatrial node. Overall HCN channels are predominantly expressed in human heart, central and peripheral neurons, and photoreceptors in retina ([@b40-ijo-49-01-0225]). HCN channels account for the rhythmic activity of cells in the sinoatrial node of heart and neurons due to their spontaneous, repetitive depolarization ([@b47-ijo-49-01-0225],[@b48-ijo-49-01-0225]).

A variety of ion channels have been implicated in malignancies and can function to regulate tumor cell survival, proliferation, growth and metastasis ([@b49-ijo-49-01-0225]), therefore, ion channels may be employed as drug targets. However, it remains challenging to define the role of an individual ion channel in malignancy. There is no inherited HCN2 mutation reported in human diseases, although acquired dysfunction of HCN2 has been reported in epilepsy and neuropathic pain ([@b50-ijo-49-01-0225]).

HCNs including HCN2 have not been studied in salivary gland tumors and any other type of tumor, except that HCN2 was reported to be overexpressed in lung carcinoma cells in which HCN2 acted as an upstream regulator of cell apoptosis induced by Ca^2+^ overload by protein kinase C inhibitors ([@b51-ijo-49-01-0225]). Although HCN2 normally conducts K^+^ and Na^+^ ([@b44-ijo-49-01-0225],[@b46-ijo-49-01-0225]), it has been reported that HCN2 was permeable to Ca^2+^, and it was suggested that they may participate in pathological Ca^2+^ signaling when HCN2 is overexpressed ([@b52-ijo-49-01-0225]).

Since there were no reliable HCN2 antibodies available for immunohistochemical staining until now, it remained unknown whether HCN2 is overexpressed in human ACC tissues and whether these channels exist on the cell membrane. IHC staining was done on our ACC TMA sections. We found that the hypomethylation of the HCN2 promoter did not increase the number of cells with HCN2 expression in ACC tumor samples, though there did appear to be an increase in staining intensity compared with the normal control samples.

In conclusion, through our screening and sequencing, we have identified hypomethylation of HCN2 as a potential biomarker for ACC that may be associated with more aggressive disease. The functional role of HCN2 remains to be seen, and as viable cell lines of ACC are more available, this can be further explored.
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![The schematic illustration by MethPrimer of the CpG islands and CpG dinucleotides in the HCN2 proximal promoter (2650 bp), 5′-UTR exon (53 bp to the start codon, ATG), and first CDS exon (632 bp including ATG). The total sequence length: 4685 bp. The island 1 (far left) is 140 bp (1615-1754); island 2 is 162 bp (2081-2242); the island 3 is 112 bp (2466-2577), the island 4 is 167 bp (2647-2813), and the island 5 (far right) that is composed of 5′-UTR exon, first CDS exon, and the proximal part of the first intron is 2290 bp (2202-4491). F4 and R4 are the primers used for bisulfite sequencing (BS-seq).](IJO-49-01-0225-g00){#f1-ijo-49-01-0225}

![The schematic illustration of the regions in the proximal HCN2 promoter that are validated by bisulfite sequencing (BS-seq) and qMSP. BS-seq-F, bisulfite sequencing forward primer; BS-seq-R, bisulfite sequencing reverse primer; qMSP-F, qMSP forward primer; qMSP-R, qMSP reverse primer; qMSP-Probe, qMSP probe. All numberings are in reference to the start codon, ATG.](IJO-49-01-0225-g01){#f2-ijo-49-01-0225}

![qMSP validation of the differential methylation status in the proximal region of HCN2 promoter detected by methylation array. qMSP validation was done between control (n=20) and ACC (n=32) cases in a separate, large FFPE cohort. P=0.04 between control and ACC cases.](IJO-49-01-0225-g02){#f3-ijo-49-01-0225}

![HCN2 methylation status is correlated with any recurrence (regional, local or distant) after primary treatment in ACC cases. 'No' means ACC cases that had no recurrence after primary treatment (n=16). 'Yes' means ACC cases that had any recurrence after primary treatment (n=15). P=0.02 by the non-parametric Wilcoxon rank-sum test between 'No' and 'Yes'.](IJO-49-01-0225-g03){#f4-ijo-49-01-0225}

![Disease-free survival curve and overall survival curve by the methylation level in the proximal region of HCN2 promoter. No statistical significance was found for each curve by the log-rank test (P=0.78 or P=0.56).](IJO-49-01-0225-g04){#f5-ijo-49-01-0225}

![The comparisons of H-scores between control and ACC cases. H-scores (P=0.01) were statistically significant between control and ACC cases.](IJO-49-01-0225-g05){#f6-ijo-49-01-0225}

![The comparisons of staining intensity between control and ACC cases. Staining intensity (P\<0.001) was statistically significant between control and ACC cases.](IJO-49-01-0225-g06){#f7-ijo-49-01-0225}

![The comparisons of percentage of the positively stained cells between control and ACC cases. The percentage of the positively stained cells (P=0.1) was not statistically significant between control and ACC cases.](IJO-49-01-0225-g07){#f8-ijo-49-01-0225}

###### 

Top 32 genes detected by methylation array.

  Gene symbol   Rank in the gene list   Probe Set ID   Normal                                              ACC
  ------------- ----------------------- -------------- --------------------------------------------------- ------
  RGPD3         1                       cg06148997     6/6                                                 6/6
  ABLIM2        9                       cg18665513     0/6                                                 0/6
  ZNF653        11                      cg13798986     0/6                                                 0/6
  ATF4          12                      cg13462160     0/6                                                 0/6
  BCL2          16                      cg06881186     0/6                                                 0/6
  PCMT1         20                      cg07671221     0/6                                                 0/6
  TNFRSF11A     23                      cg19524723     0/6                                                 0/6
  ZNF527        28                      cg09011348     0/6                                                 0/6
  SIM2          31                      cg21697851     0/6                                                 0/6
  PINX1         39                      cg26027776     0/6                                                 0/6
  ZNF703        45                      cg25487404     0/6                                                 0/6
  HCN2          47                      cg25367758     6/6[a](#tfn2-ijo-49-01-0225){ref-type="table-fn"}   0/6
  POU4F3        49                      cg04701505     0/6                                                 0/6
  EXOSC2        52                      cg14638609     0/6                                                 0/6
  ZNF749        53                      cg23077461     0/6                                                 0/6
  DUSP4         55                      cg05972070     0/6                                                 0/6
  LGI3          62                      cg18317494     0/6                                                 0/6
  PEX5          68                      cg07748017     0/6                                                 0/6
  FBXO41        87                      cg02063488     0/6                                                 0/6
  GPR39         97                      cg19309079     0/6                                                 0/6
  RUNX3         128                     cg27360282     0/6                                                 0/6
  BHLHE41       130                     cg19243777     0/6                                                 0/6
  GPR123        196                     cg20559403     0/6                                                 0/6
  SOX21         287                     cg18368297     0/6                                                 0/6
  TBX2          292                     cg27470066     0/6                                                 0/6
  EHD1          652                     cg21739289     0/6                                                 0/6
  TOLLIP        2012                    cg12308164     0/6                                                 0/6
  FRMD6         4423                    cg09410986     6/6                                                 6/6
  BSG           7360                    cg10362365     0/6                                                 N.D.
  MALT1         9548                    cg21074092     0/6                                                 0/6
  MORN1         10003                   cg22045975     0/6                                                 0/6
  CT62          26514                   cg13125884     0/6                                                 0/6

N.D., no data;

5 CpG sites were methylated in all 6 normal samples, whereas other 5 CpG sites were methylated in most of 6 normal samples.

###### 

The schematic illustration of 10 CpG dinucleotides in the proximal region of HCN2 promoter and their methylation status validated by bisulfite sequencing in a small validation cohort of 6 normal and 6 ACC tumor samples.

       CpG 1   CpG 2   CpG 3   CpG 4   CpG 5   CpG 6   CpG 7   CpG 8   CpG 9   CpG 10
  ---- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  N1   ●       ●       ●       ●       ●       ●       ●       ●       ●       ●
  N2   ●       ●       ●       ●       ●       ○       ●       ●       ○       ○
  N3   ○       ●       ●       ●       ●       ○       ●       ○       ○       ●
  N4   ●       ●       ●       ●       ●       ○       ●       ●       ●       ●
  N5   ●       ●       ●       ●       ●       ●       ●       ●       ●       ●
  N6   ●       ●       ●       ●       ●       ●       ●       ●       ●       ●
  T1   ○       ○       ○       ○       ○       ○       ○       ○       ○       ○
  T2   ○       ○       ○       ○       ○       ○       ○       ○       ○       ○
  T4   ○       ○       ○       ●       ○       ○       ○       ○       ○       ○
  T4   ○       ○       ○       ○       ○       ○       ○       ○       ○       ○
  T5   ○       ○       ○       ○       ○       ○       ○       ○       ○       ○
  T6   ○       ○       ○       ○       ○       ○       ○       ○       ○       ○

●, methylation; ○, unmethylation. ACC, adenoid cystic carcinoma. N1-N6, 6 DNA samples from 6 normal salivary gland tissues; T1-T6, 6 DNA samples from 6 ACC tissues. CpG 1--10 are 10 CpG dinucleotides that were reliably sequenced by bisulfite sequencing in each PCR product of these 12 DNA samples.

###### 

The correlation of the clinical variables and patient outcomes with the median HCN2 promoter methylation status in a proximal region detected by the methylation array.

  Variables                                                      n    Median methylation level of HCN2 (IQR)   P-value
  -------------------------------------------------------------- ---- ---------------------------------------- ---------
  Tumor vs. control (n=52)                                                                                     0.04
   Control                                                       20   14.1 (0--28.3)                           
   Case                                                          32   0.4 (0--9.5)                             
  Tumor only (n=31)                                                                                            
  Gender                                                                                                       0.25
   Male                                                          11   0.7 (0--25.9)                            
   Female                                                        20   0.09 (0--8.1)                            
  Age (years)                                                                                                  0.68
   \<50                                                          17   0.7 (0--9.5)                             
   50+                                                           14   0.3 (0--7.1)                             
  Smoking history                                                                                              0.89
   No                                                            16   1.0 (0--9.5)                             
   Yes                                                           13   0.2 (0--10.5)                            
  Site                                                                                                         0.48
   Major                                                         14   0.6 (0--9.4)                             
   Minor                                                         17   0.6 (0--20.0)                            
  T-stage                                                                                                      0.76
   I--II                                                         11   4.8 (0--9.5)                             
   III--IV                                                       16   1.0 (0--15.3)                            
  N-stage                                                                                                      0.44
   0                                                             21   4.8 (0--16)                              
   1+                                                            6    0.4 (0--7.1)                             
  M-stage                                                                                                      0.53
   0                                                             24   1.0 (0--10.0)                            
   1                                                             3    7.1 (0--96.4)                            
  Overall stage                                                                                                0.79
   I--II                                                         9    5.4 (0--9.5)                             
   III--IV                                                       18   0.6 (0--10.5)                            
  Margin                                                                                                       0.34
   Negative/close                                                6    0.10 (0--9.5)                            
   Positive                                                      21   4.8 (0--10.5)                            
  Pattern                                                                                                      0.10
   Cribriform or tubular                                         26   3.0 (0--10.5)                            
   Solid                                                         2    0 (0--0)                                 
  Nodal metastases on neck dissection                                                                          0.63
   No                                                            9    4.8 (0--9.4)                             
   Yes                                                           6    0.4 (0--7.1)                             
  Perineural invasion                                                                                          0.09
   No                                                            1    39.7 (n/a)                               
   Yes                                                           18   0.6 (0--5.4)                             
  MYB-NFIB translocation                                                                                       0.22
   Negative                                                      11   6.7 (0--16.0)                            
   Positive                                                      14   0.4 (0--7.1)                             
  Any recurrence[a](#tfn5-ijo-49-01-0225){ref-type="table-fn"}                                                 0.02
   No                                                            14   5.4 (0.2--16.0)                          
   Yes                                                           14   0 (0--4.8)                               
  Local recurrence                                                                                             0.03
   No                                                            22   3.0 (0--10.5)                            
   Yes                                                           9    0 (0--0)                                 
  Regional recurrence                                                                                          0.30
   No                                                            30   0.6 (0--9.5)                             
   Yes                                                           1    0 (n/a)                                  
  New distant metastases                                                                                       0.05
   No                                                            20   4.0 (0--13.3)                            
   Yes                                                           11   0 (0--4.8)                               
  Vital status at last follow-up                                                                               0.10
   Alive                                                         14   7.1 (0--16.0)                            
   Expired                                                       17   0 (0--5.4)                               

IQR, interquartile range;

any recurrence denotes a regional, local, or distant recurrence after primary treatment, excluding cases with distant metastases at presentation.

n/a, not applicable.

###### 

Survival by promoter methylation level of HCN2 gene among ACC cases.

                                                                     Disease-free survival   Overall survival                  
  ------------------------------------------------------------- ---- ----------------------- ------------------ -------------- ------
  HCN2, also see [Fig. 5](#f5-ijo-49-01-0225){ref-type="fig"}                                0.78                              0.56
   \< median                                                    16   124.9 (20.5)                               180.0 (62.5)   
   ≥ median                                                     16   93.5 (33.6)                                163.7 (13.5)   

ACC, adenoid cystic carcinoma; SE, standard error.

###### 

HCN2 IHC analysis between normal control and ACC cases.

  Score                                                                         ACC cases median (IQR) (n=93)   Controls median (IQR) (n=10)   P-value
  ----------------------------------------------------------------------------- ------------------------------- ------------------------------ ---------
  HCN2 H-score also see [Fig. 6](#f6-ijo-49-01-0225){ref-type="fig"}            27 (10--77)                     60 (60--90)                    0.01
  HCN2 intensity also see [Fig. 7](#f7-ijo-49-01-0225){ref-type="fig"}          2 (1--2)                        3 (3--3)                       \<0.001
  HCN2 percent staining also see [Fig. 8](#f8-ijo-49-01-0225){ref-type="fig"}   13 (5--33)                      20 (20--30)                    0.10

IHC, immunohistochemical staining; ACC, adenoid cystic carcinoma; IQR, interquartile range.
